Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents

Progress in Brain Research

Volumn 170, Issue , 2008, Pages 473-512

  Manning, Maurice ^a   Stoev, Stoytcho ^a   Chini, Bice ^b   Durroux, Thierry ^c   Mouillac, Bernard ^c   Guillon, Gilles ^c  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b CNR   (Italy)

^c CNRS   (France)

Author keywords

agonist; antagonist; bivalent; non peptide; oxytocin; radiolabelled; vaptans; vasopressin

Indexed keywords

1 [1 [4 (1 ACETYL 4 PIPERIDINYLOXY) 2 METHOXYBENZOYL] 4 PIPERIDINYL]BENZ[D][1,3]OXAZIN 2 ONE; 1 [1 [4 (3 ACETAMIDOPROPOXY)BENZOYL] 4 PIPERIDYL] 1,2,3,4 TETRAHYDRO 2 QUINOLINONE; 1 [5 CHLORO 1 (2,4 DIMETHOXYLPHENYLSULFONYL) 2,3 DIHYDRO 3 (2 METHOXYPHENYL) 2 OXO 1H INDOL 3 YL] 4 HYDROXY N,N DIMETHYL 2 PYRROLIDINECARBOXAMIDE; 1 [[[2 [2 AMINO 4 (METHYLSULFONYL)BUTYRAMIDO] 7,7 DIMETHYLBICYCLO[2.2.1]HEPTAN 1 YL]METHYL]SULFONYL] 4 (2 METHYLPHENYL)PIPERAZINE; 1,4 DIHYDRO 1 [1 [2 METHOXY 4 [1 (2 METHYL 1 OXIDO 3 PYRIDINYLMETHYL) 4 PIPERIDINYLOXY]BENZOYL] 4 PIPERIDINYL]BENZ[D][1,3]OXAZIN 2 ONE; ATOSIBAN; BARUSIBAN; CL 385004; CONIVAPTAN; FR 161282; LIXIVAPTAN; MOZAVAPTAN; ORG 52186; OXYTOCIN ANTAGONIST; PEPTIDE DERIVATIVE; RELCOVAPTAN; RWJ 351467; RWJ 351647; SATAVAPTAN; SRX 251; SSR 126768A; TOLVAPTAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOPRESSIN ANTAGONIST; VP 339; VP 343; VP 365; WAY 140288; WAY 162720; YM 218; YM 471;

AGONIST; ANTIDIURESIS; ANXIETY DISORDER; BINDING AFFINITY; BIOASSAY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG APPROVAL; DRUG POTENCY; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPONATREMIA; ISOTOPE LABELING; KIDNEY POLYCYSTIC DISEASE; LIVER CIRRHOSIS; NONHUMAN; PEPTIDE SYNTHESIS; PREMATURE LABOR; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; UNITED STATES;

ANIMALS; ANTIDIURETIC AGENTS; BENZAZEPINES; CLINICAL TRIALS AS TOPIC; DEAMINO ARGININE VASOPRESSIN; FEMALE; HUMANS; HYPONATREMIA; LYSINE VASOPRESSIN; OLIGOPEPTIDES; OXYTOCIN; PEPTIDES; RATS; RECEPTORS, OXYTOCIN; RECEPTORS, VASOPRESSIN; STRUCTURE-ACTIVITY RELATIONSHIP; UTERUS; VASODILATOR AGENTS; VASOPRESSINS;

EID: 47649122194     PISSN: 00796123     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0079-6123(08)00437-8     Document Type: Review

References (288)

1. 2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J. Am. Coll. Cardiol. 47 (2006) 1615-1621
2. Akerlund M. Targeting the oxytocin receptor to relax the myometrium. Expert Opin. Ther. Targets 10 (2006) 423-427
3. 1a receptors. Eur. J. Pharmacol. 331 (1997) 285-293
4. 2 receptors. J. Med. Chem. 41 (1998) 2442-2444
5. Ali F., Guglin M., Vaitkevicius P., and Ghali J.K. Therapeutic potential of vasopressin receptor antagonists. Drugs 67 (2007) 847-858
6. Andres M., Pena A., Derick S., Raufaste D., Trojnar J., Wisniewski K., Trueba M., Serradeil-Le-Gal C., and Guillon G. Comparative pharmacology of bovine, human and rat vasopressin receptor isoforms. Eur. J. Pharmacol. 501 (2004) 59-69
7. Andres M., Trueba M., and Guillon G. Pharmacological characterization of F-180: a selective human V(1a) vasopressin receptor agonist of high affinity. Br. J. Pharmacol. 135 (2002) 1828-1836
8. Antoni F.A. Novel ligand specificity of pituitary vasopressin receptors in the rat. Neuroendocrinology 39 (1984) 186-188
9. Aranapakam V., Albright J.D., Grosu G.T., Delos Santos E.G., Chan P.S., Coupet J., Ru X., Saunders T., and Mazandarani H. 5-fluoro-2-methyl-N-[5-(5H-pyrrolo[2,1-c][1,4]benzodiazepine-10(11H)-yl carbonyl)-2-pyridinyl]benzamide (CL-385004) and analogs as orally active arginine vasopressin receptor antagonists. Bioorg. Med. Chem. Lett. 9 (1999) 1737-1740
10. 1b receptors: new probes for therapy. Endocrinology 148 (2007) 4133-4135
11. 2-receptor antagonists optimized for parenteral delivery. Bioorg. Med. Chem. Lett. 10 (2000) 783-786
12. Ashworth D.M., Batt A.R., Baxter A.J., Broqua P., Haigh R.M., Hudson P., Heeney C.M.S., Laporte R., Penson A., Pitt G.R.W., Robson P.A., Rooker D.P., Tartar A.L., Yea C.M., and Roe M.B. Nonpeptide oxytocin agonists. Drugs Future 31 (2006) 345-353
13. Assinder S.J., Johnson C., King K., and Nicholson H.D. Regulation of 5 alpha-reductase isoforms by oxytocin in the rat ventral prostate. Endocrinology 145 (2004) 5767-5773
14. Aurell C.J., Bengtsson B., Ekholm K., Kasprzykowska R., Nilsson A., Persson R., Trojnar J., Abbe M., and Melin P. Development of vasopressor specific vasotocin analogues with prolonged effects. In: Giralt E., and Andreu D. (Eds). Peptides (1990) (1991), Escom Science Publishers, Leiden 671-673
15. Bankowski K., Manning M., Seto J., Haldar J., and Sawyer W.H. Design and synthesis of potent in vivo antagonists of oxytocin. Int. J. Pept. Protein Res. 16 (1980) 382-391
16. 1a receptors. Neuroendocrinology 62 (1995) 135-146
17. Barberis C., Morin D., Durroux T., Mouillac B., Guillon G., Seyer R., Hibert M., Tribollet E., and Manning M. Molecular pharmacology of AVP and OT receptors and therapeutic potential. Drug News Perspect. 12 (1999) 279-292
18. Belec L., Blankenship J.W., and Lubell W.D. Examination of structural characteristics of the potent oxytocin antagonists [dPen1,Pen6]-OT and [dPen1,Pen6,5-tBuPro7]-OT by NMR, Raman, CD spectroscopy and molecular modeling. J. Pept. Sci. 11 (2005) 365-378
19. Bell I.M., Erb J.M., Freidinger R.M., Gallicchio S.N., Guare J.P., Guidotti M.T., Halpin R.A., Hobbs D.W., Homnick C.F., Kuo M.S., Lis E.V., Mathre D.J., Michelson S.R., Pawluczyk J.M., Pettibone D.J., Reiss D.R., Vickers S., Williams P.D., and Woyden C.J. Development of orally active oxytocin antagonists: Studies on 1-(1-(4-[1-(2-Methyl-1-oxidopyridin-3ylmethyl)piperidin-4-yloxy]-2-metho xybenzoyl)piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines. J. Med. Chem. 41 (1998) 2146-2163
20. Berde B., and Boissonnas R.A. Basic pharmacological properties of synthetic analogues and homologues of the neurohypophysial hormones. In: Berde B. (Ed). Neurohypophysial Hormones and Similar Polypeptides, Handbook of Experimental Pharmacology 23 (1968), Springer Verlag, Berlin 802-870
21. Bernadich C., Bandi J.C., Melin P., and Bosch J. Effects of F-180, a new selective vasoconstrictor peptide, compared with terlipressin and vasopressin on systemic and splanchnic hemodynamics in a rat model of portal hypertension. Hepatology 27 (1998) 351-356
22. Bernier V., Morello J.P., Zarruk A., Debrand N., Salahpour A., Lonergan M., Arthus M.F., Laperriere A., Brouard R., Bouvier M., and Bichet D.G. Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. J. Am. Soc. Nephrol. 17 (2006) 232-243
23. Birnbaumer M., Seibold A., Gilbert S., Ishido M., Barberis C., Antaramian A., Brabet P., and Rosenthal W. Molecular cloning of the receptor for human antidiuretic hormone. Nature 357 (1992) 333-335
24. Boccia M.L., Goursaud A.P., Bachevalier J., Anderson K.D., and Pedersen C.A. Peripherally administered non-peptide oxytocin antagonist, L368,899(R), accumulates in limbic brain areas: a new pharmacological tool for the study of social motivation in non-human primates. Horm. Behav. 52 (2007) 344-351
25. Bone E.A., Fretten P., Palmer S., Kirk C.J., and Michell R.H. Rapid accumulation of inositol phosphates in isolated rat superior cervical sympathetic ganglia exposed to V1-vasopressin and muscarinic cholinergic stimuli. Biochem. J. 221 (1984) 803-811
26. Bosch O.J., Kromer S.A., and Neumann I.D. Prenatal stress: opposite effects on anxiety and hypothalamic expression of vasopressin and corticotrophin-releasing hormone in rats selectivity bred for high and low anxiety. Eur. J. Neurosci. 23 (2006) 541-551
27. Bosch O.J., Meddle S.L., Beiderbeck D.I., Douglas A.J., and Neumann I.D. Brain oxytocin correlates with maternal aggression: link to anxiety. J. Neurosci. 25 (2005) 6807-6815
28. Buku A., and Gazis D. Probes for vasopressin receptors. Attachment of affinity and fluorescent groups in vasopressin. Int. J. Pept. Protein Res. 35 (1990) 128-132
29. Buku A., Masur S., and Eggena P. Synthesis and characterization of fluorescein- and rhodamine-labeled probes for vasotocin receptors. Am. J. Physiol. 257 (1989) E804-E808
30. Buku A., Yamin N., and Gazis D. Fluorescent, photoaffinity, and biotinyl analogs of oxytocin. Peptides 9 (1988) 783-786
31. Butlen B., Guillon G., Rajerison R.M., Jard S., Sawyer W.H., and Manning M. Structural requirements for activation of vasopressin-sensitive adenylate cyclase, hormone binding, and antidiuretic actions: effects of highly potent analogues and competitive inhibitors. Mol. Pharmacol. 14 (1978) 1006-1017
32. 3H)-vasopressin binding to isolated rat hepatocytes and liver membranes: regulation by GTP and relation to glycogen phosphorylase activation. J. Recept. Res. 1 (1980) 137-168
33. Cassoni P., Marrocco T., Bussolati B., Allia E., Munaron L., Sapino A., and Bussolati G. Oxytocin induces proliferation and migration in immortalized human dermal microvascular endothelial cells and human breast tumor-derived endothelial cells. Mol. Cancer Res. 4 (2006) 351-359
34. Cawley M.J. Hyponatremia: current treatment strategies and the role of vasopressin antagonists. Ann. Pharmacother. 41 (2007) 840-850
35. Cecanho R., De Luca Jr. L.A., and Ranali J. Cardiovascular effects of felypressin. Anesth. Prog. 53 (2006) 119-125
36. Chan W.Y., and Kelly N. A pharmacological analysis on the significance of the chemical functional groups of oxytocin to its oxytocic activity and on the effect of magnesium on the in vitro and in vivo oxytocic activity of neurohypophysial hormones. J. Pharmacol. Exp. Ther. 156 (1967) 150-158
37. Chan W.Y., Levi R., Wo N.C., Koyama M., Stoev S., Cheng L.L., and Manning M. Novel selective hypotensive vasopressin peptides: cardiovascular and structure-activity-relationship studies. Eur. J. Pharmacol. 419 (2001) 65-72
38. 1a receptor antagonists: new approaches for the design of potential tocolytics for preterm labor. J. Pharmacol. Exp. Ther. 277 (1996) 999-1003
39. Chan W.Y., Wo N.C., Stoev S., Cheng L.L., and Manning M. Discovery of novel selective hypotensive vasopressin peptides that exhibit little or no functional interactions with known oxytocin/vasopressin receptors. Br. J. Pharmacol. 125 (1998) 803-811
40. Chan W.Y., Wo N.C., Stoev S., Cheng L.L., and Manning M. Discovery and design of novel and selective vasopressin and oxytocin agonists and antagonists: the role of bioassays. Exp. Physiol. 85 Suppl. 1 (2000) 7S-18S
41. Chandrashekhar Y., Prahash A.J., Sen S., Gupta S., Roy S., and Anand I.S. The role of arginine vasopressin and its receptors in the normal and failing rat heart. J. Mol. Cell. Cardiol. 35 (2003) 495-504
42. Chen S., Jalandhara N., and Battle D. Evaluation and management of hyponatremia: an emerging role for vasopressin receptor antagonists. Nat. Clin. Pract. Nephrol. 3 (2007) 82-95
43. 1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J. Med. Chem. 47 (2004) 2375-2388
44. Chini B., and Manning M. Agonist selectivity in the oxytocin/vasopressin receptor family: new insights and challenges. Biochem. Soc. Trans. 35 (2007) 737-741
45. Chini B., Manning M., and Guillon G. Affinity and efficacy of selective agonists and antagonists for vasopressin and oxytocin receptors: an "easy guide" to receptor pharmacology. In: Landgraf R., and Neuman I. (Eds). Advances in Vasopressin and Oxytocin from Genes to Behavior and Disease, Progress in Brain Research (2008), Elsevier, Amsterdam 170
46. Chini B., Stoev S., Cheng L.L., and Manning M. The first bivalent ligands for oxytocin and vasopressin receptors. In: Rolka K., Rekowski P., and Silberring J. (Eds). Peptides 2006 (2007), Kenes International, Geneva 744-745
47. Cirillo R., Gillio Tos E., Schwarz M.K., Quattropani A., Scheer A., Missotten M., Dorbais J., Nichols A., Borrelli F., Giachetti C., Golzio L., Marinelli P., Thomas R.J., Chevillard C., Laurent F., Portet K., Barberis C., and Chollet A. Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino)-1-[2′-me thyl[1,1′-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamine, a new potent and selective nonpeptide antagonist of the oxytocin receptor. J. Pharmacol. Exp. Ther. 306 (2003) 253-261
48. Condes-Lara M., Rojas-Piloni G., Martinez-Lorenzana G., Rodrigues-Jimenez J., Lopez Hidalgo M., and Freund-Mercier M.J. Paraventricular hypothalamic influences on spinal nociceptive processing. Brain Res. 1081 (2006) 126-137
49. 2 vasopressin receptor. J. Biol. Chem. 273 (1998) 29462-29468
50. 1b receptor antagonist. In: Landgraf R., and Neuman I. (Eds). Advances in Vasopressin and Oxytocin from Genes to Behavior and Disease. Progress in Brain Research (2008), Elsevier, Amsterdam 170
51. 1a receptors-mediated effects in the central cardiovascular control during the post-infarct state. Regul. Pept. 142 (2007) 86-94
52. Cumbers M.R., Chung S.T., and Wakerley J.B. A neuromodulatory role for oxytocin within the supramammillary nucleus. Neuropeptides 41 (2007) 217-226
53. Daniels D.J., Lenard N.R., Etienne C.L., Law P.Y., Roerig S.C., and Portoghese P.S. Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 19208-19213
54. Dawwas M.F. Tolvaptan for hyponatremia. N. Engl. J. Med. 356 (2007) 961-962
55. Dekanski J. The quantitative assay of vasopressin. Br. J. Pharmacol. 7 (1952) 567-572
56. 3 pituitary vasopressin receptor. FEBS Lett. 356 (1994) 215-220
57. 1b receptors. Endocrinology 143 (2002) 4655-4664
58. 1b vasopressin receptor. Mol. Endocrinol. 18 (2004) 2777-2789
59. Detillion C.E., Craft T.K., Glasper E.R., Prendergast B.J., and DeVries A.C. Social facilitation of wound healing. Psychoneuroendocrinology 29 (2004) 1004-1011
60. 1 receptors in cardiovascular responses to stress in rats with myocardial infarction. Stress 8 (2005) 273-284
61. Douglas, A., Leng, G., Ludwig, M. and Russell, J.A. (Eds.) (2000) Oxytocin and vasopressin - from molecules to function. Exp. Physiol. 85S (Special edition): 1S-272S.
62. Durroux T., Peter M., Turcatti G., Chollet A., Balestre M.N., Barberis C., and Seyer R. Fluorescent pseudo-peptide linear vasopressin antagonists: design, synthesis, and applications. J. Med. Chem. 42 (1999) 1312-1319
63. du Vigneaud V., Gish D.T., and Katsoyannis P.G. A synthetic preparation possessing biological properties associated with arginine-vasopressin. J. Am. Chem. Soc. 76 (1954) 4751-4752
64. du Vigneaud V., Ressler C., Swan J.M., Roberts C.W., and Katsoyannis P.G. The synthesis of oxytocin. J. Am. Chem. Soc. 76 (1954) 3115-3121
65. Dyckes D.F., Ferger M.F., and du Vigneaud V. Synthesis and some of the pharmacological properties of [4-leucine]-8-lysine-vasopressin and [1-deamino, 4-leucine]-8-lysine-vasopressin. J. Med. Chem. 16 (1973) 843-847
66. Dyckes D.F., Nestor Jr. J.J., Ferger M.F., and du Vigneaud V. [1-β-mercapto-β,β-diethylpropionic acid]-8-lysine-vasopressin, a potent inhibitor of 8-lysine-vasopressin and of oxytocin. J. Med. Chem. 17 (1974) 250-252
67. Ebner K., Bosch O.J., Kromer S.A., Singewald N., and Neumann I.D. Release of oxytocin in the rat central amygdala modulates stress-coping behavior and the release of excitatory amino acids. Neuropsychopharmacology 30 (2005) 223-230
68. Eggena P., and Buku A. Synthesis and characterization of a long-acting fluorescent analog of vasotocin. Biol. Cell. 66 (1989) 1-6
69. 9]OVT: a selective oxytocin receptor ligand. Eur. J. Pharmacol. 147 (1988) 197-207
70. Evans B.E., Leighton J.L., Rittle K.E., Gilbert K.F., Lundell G.F., Gould N.P., Hobbs D.W., DiPardo R.M., Veber D.F., and Pettibone D.J. Orally active, nonpeptide oxytocin antagonists. J. Med. Chem. 35 (1992) 3919-3927
71. 2 receptor selective agonists. Bioorg. Med. Chem. Lett. 16 (2006) 954-959
72. 1a receptor antagonist, SRX251, selectively blocks aggressive behavior. Pharmacol. Biochem. Behav. 83 (2006) 169-174
73. Flouret G., Chaloin O., Borovickova L., and Slaninova J. Design of novel bicyclic analogues derived from a potent oxytocin antagonist. J. Pept. Sci. 12 (2006) 412-419
74. Fragiadaki M., Magafa V., Borovickova L., Slaninova J., and Cordopatis P. Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7. Eur. J. Med. Chem. 42 (2007) 799-806
75. Freidinger R.M., and Pettibone D.J. Small molecule ligands for oxytocin and vasopressin receptors. Med. Res. Rev. 17 (1997) 1-16
76. Gera L., Stewart J.M., Whalley E.T., Burkard M., and Zuzack J.S. New bradykinin antagonists having very high potency at B1 receptors. Immunopharmacology 33 (1996) 183-185
77. 2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J. Clin. Endocrinol. Metab. 91 (2006) 2145-2152
78. Gheorghiade M., Konstam M.A., Burnett Jr. J.C., Grinfeld L., Maggioni A.P., Swedberg K., Udelson J.E., Zannad F., Cook T., Ouyang J., Zimmer C., and Orlandi C. Efficacy of vasopressin antagonism in heart failure outcome study with Tolvaptan (EVEREST) investigator. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 297 (2007) 1332-1343
79. Gimpl G., and Fahrenholz F. The oxytocin receptor system: structure function and regulation. Physiol. Rev. 81 (2001) 629-683
80. Gines P. Vaptans: a promising therapy in the management of advanced cirrhosis. J. Hepatol. 46 (2007) 1150-1152
81. 1b receptor antagonist, SSR 149415, suggest an innovative approach for the treatment of stress-related disorders. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 6370-6375
82. 1b/oxytocin receptor antagonist. Br. J. Pharmacol. 146 (2005) 744-751
83. 1a antagonists. Bioorg. Med. Chem. 15 (2007) 2054-2080
84. Guillon G., Barbeau D., Neugebauer W., Guay S., Bilodeau L., Balestre M.N., Gallo-Payet N., and Escher E. Fluorescent peptide hormones: development of high affinity vasopressin analogues. Peptides 13 (1992) 7-11
85. 1b receptor ligands for pharmacological, functional and structural investigations. J. Neuroendocrinol. 16 (2004) 356-361
86. 1b receptors. In: Rolka K., Rekowski P., and Silberring J. (Eds.), Peptides 2006. Kenes International, Geneva, pp. 740-741.
87. Guillon G., Pena A., Murat B., Derick S., Trueba M., Ventura M.A., Szeto H.H., Wo N., Stoev S., Cheng L.L., and Manning M. Position 4 analogues of [deamino-Cys(1)]arginine vasopressin exhibit striking species differences for human and rat V(2)/V(1b) receptor selectivity. J. Pept. Sci. 12 (2006) 190-198
88. 2 receptor antagonist. Clin. Exp. Pharmacol. Physiol. 33 (2006) 320-326
89. Hagedorn T.M., Carlin R.W., and Schultz B.D. Oxytocin and vasopressin stimulate anion secretion by human and porcine vas deferens epithelia. Biol. Reprod. 77 (2007) 416-424
90. Halazy S. G-protein coupled receptors bivalent ligands and drug design. Exp. Opin. Ther. Pat. 9 (1999) 431-446
91. Hammock E.A., and Young I.J. Oxytocin, vasopressin and pair bonding: implications for autism. Philos. Trans. R. Soc. Lond. B Biol. Sci. 361 (2006) 2187-2198
92. Hansenne I., Rasier G., Pequeux C., Brilot F., Renard C.H., Breton C., Greimers R., Legros J.J., Geenen V., and Martens H.J. Ontogenesis and functional aspects of oxytocin and vasopressin gene expression in the thymus network. J. Neuroimmunol. 158 (2005) 67-75
93. 2 receptors in the mouse kidney. Physiol. Genomics 21 (2005) 382-388
94. Hawtin S.R., Ha S.N., Pettibone D.J., and Wheatley M. A Gly/Ala switch contributes to high affinity binding of benzoxazinone-based non-peptide oxytocin receptor antagonists. FEBS Lett. 579 (2005) 349-356
95. Hays R.M. Vasopressin antagonists - progress and promise. N. Engl. J. Med. 355 (2006) 2146-2148
96. 2 receptor. J. Clin. Invest. 84 (1989) 418-426
97. Hollander E., Bartz J., Chaplin W., Phillips A., Sumner J., Soorya L., Anagnostou E., and Wasserman S. Oxytocin increases retention of social cognition in autism. Biol. Psychiatry 61 (2007) 498-503
98. Hollander E., Novotny S., Hanratty M., Yaffe R., DeCaria C.M., Aronowitz B.R., and Mosovich S. Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders. Neuropsychopharmacology 28 (2003) 193-198
99. Holmes C.L., Landry D.W., and Granton J.T. Science review: vasopressin and the cardiovascular system part 1 - receptor physiology. Crit. Care 7 (2003) 427-434
100. Holmes C.L., Landry D.W., and Granton J.T. Science review: vasopressin and the cardiovascular system part 2 - clinical physiology. Crit. Care 8 (2004) 15-23
101. Holton P.A. A modification of the method of Dale and Laidlaw for standardization of posterior pituitary extract. Br. J. Pharmacol. 3 (1948) 328-334
102. Hoorn E.J., and Zietse R. Tolvaptan for hyponatremia. N. Engl. J. Med. 356 (2007) 961
103. Howl J., Ismail T., Strain A.J., Kirk C.J., Anderson D., and Wheatley M. Characterization of the human liver vasopressin receptor. Profound differences between human and rat vasopressin-receptor-mediated responses suggest only a minor role for vasopressin in regulating human hepatic function. Biochem. J. 276 (1991) 189-195
104. Howl J., Langel U., Hawtin S.R., Valkna A., Yarwood N.J., Saar K., and Wheatley M. Chimeric strategies for the rational design of bioactive analogs of small peptide hormones. FASEB J. 11 (1997) 582-590
105. 1a vasopressin receptor. Eur. J. Biochem. 213 (1993) 711-719
106. Hruby, V.J. and Smith, C.W. (1987) Structure-activity relationships of neurohypophysial peptides. In: Smith C.W. (Eds.), Chemistry, biology, and medicine of neurohypophysial hormones and their analogs, The Peptides, S. Udenfriend and J. Meienhofer (Eds.), 8, 77-207, Orlando, FL, Academic Press.
107. Huber D., Veinante P., and Stoop R. Vasopressin and oxytocin excite distinct neuronal populations in the central amygdala. Science 308 (2005) 245-248
108. 8-ocytocine, deux analogues de la vasopressine douse d'une activité pressorique selective. Helv. Chim. Acta 47 (1964) 1934-1941
109. 8]-vasopressin, two analogues possessing an antidiuretic activity more elevated and selective than that of the natural vasopressins]. Helv. Chim. Acta 49 (1966) 696-705
110. Insel T.R., and Young L.J. The neurobiology of attachment. Nat. Rev. Neurosci. 2 (2001) 129-136
111. Janknegt R.A., Zweers H.M., Delaere K.P., Kloet A.G., Khoe S.G., and Arendsen H.J. Oral desmopressin as a new treatment modality for primary nocturnal enuresis in adolescents and adults: a double-blind, randomized, multicenter study. J. Urol. 157 (1997) 513-517
112. Jard S. Vasopressin receptors. A historical survey. In: Zingg H.H., Bourque C.W., and Bichet D.G. (Eds). Advances in Experimental Medicine and Biology (1998), Plenum Press, New York 1-13
113. Jard S., Gaillard R.C., Guillon G., Marie J., Schoenenberg P., Muller A.F., Manning M., and Sawyer W.H. Vasopressin antagonists allow demonstration of a novel type of vasopressin receptor in the rat adenohypophysis. Mol. Pharmacol. 30 (1986) 171-177
114. Jost K., Lebl M., and Brtnik F. Handbook of Neurohypophyseal Hormone Analogs, Vol. 2, Parts I and II (1988), CRC Press, Boca Raton, FL
115. Kawata, M. and Leng, G. (Eds.) (2004) Neurohypophysial hormones. J. Neuroendocrinol. 16: 291-408.
116. Kimura T., Tanizawa O., Mori K., Brownstein M., and Okayama H. Structure and expression of a human oxytocin receptor. Nature 356 (1992) 526-529
117. Kinter L.B., Huffman W.F., and Stassen F.L. Antagonists of the antidiuretic activity of vasopressin. Am. J. Physiol. 254 (1988) F165-F177
118. Kirsch P., Esslinger C., Chen Q., Mier D., Lis S., Siddhanti S., Gruppe H., Mattay V.S., Gallhofer B., and Meyer-Lindenberg A. Oxytocin modulates neural circuitry for social cognition and fear in humans. J. Neurosci. 25 (2005) 11489-11493
119. 2 receptor agonists. Expert Opin. Ther. Pat. 12 (2002) 1249-1258
120. Kosfeld M., Heinrichs M., Zak P.J., Fischbacher U., and Fehr E. Oxytocin increases trust in humans. Nature 435 (2005) 673-676
121. 2 agonist. J. Med. Chem. 50 (2007) 2926-2929
122. Kruszynski M., Lammek B., Manning M., Seto J., Haldar J., and Sawyer W.H. [1-beta-Mercapto-beta,beta-cyclopentamethylenepropionic acid),2-(O-methyl)tyrosine]arginine-vasopressin and [1-beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)]arginine-vasopressin, two high potent antagonists of the vasopressor response to arginine-vasopressin. J. Med. Chem. 23 (1980) 364-368
123. Lam K.S., Wat M.S., Choi K.L., Ip T.P., Pang R.W., and Kumana C.R. Pharmacokinetics, pharmacodynamics, long-term efficacy and safety of oral 1-deamino-8-d-arginine vasopressin in adult patients with central diabetes insipidus. Br. J. Clin. Pharmacol. 42 (1996) 379-385
124. Lammek B., Bankowski K., Misicka A., Manning M., Seto J., and Sawyer W.H. 2-O-alkyltyrosine derivatives of 1-deamino-arginine-vasopressin: highly specific and potent antidiuretic agonists. J. Med. Chem. 32 (1989) 244-247
125. Landgraf R. The involvement of the vasopressin system in stress-related disorders. CNS Neurol. Disord. Drug Targets 5 (2006) 167-179
126. Landgraf, R. and Neumann, I. (Eds.) (2008) Advances in Vasopressin and Oxytocin: From Genes to Behavior and Disease. Progress in Brain Research. Elsevier, Amsterdam.
127. Lebl, M. (1988) In: Jost K., Lebl M. and Brtnik F. (Eds.), Handbook of Neurohypophyseal Hormone Analogs, Vol. 2, Part 1, Part 2, CRC Press: Boca Raton, FL, pp. 17-72, 127-267.
128. 3 antagonists. World Intellectual Property Organization (WIPO) Patent WO/2006/095014. Publication date: September 14, 2006.
129. 2-agonism in dogs. Am. J. Physiol. 256 (1989) H1621-H1626
130. Liu B., Hill S.J., and Khan R.N. Oxytocin inhibits T-type calcium current of human decidual stromal cells. J. Clin. Endocrinol. Metab. 90 (2005) 4191-4197
131. Liu X., Tribollet E., Ogier R., Barberis C., and Raggenbass M. Presence of functional vasopressin receptors in spinal ventral hom neurons of young rats: a morphological and electrophysiological study. Eur. J. Neurosci. 17 (2003) 1833-1846
132. Liu X., Tribollet E., and Raggenbass M. GABA(B) receptor-activation inhibits GABAergic synaptic transmission in parvocellular neurons of rat hypothalamic paraventricular nucleus. J. Neuroendocrinol. 8 (2006) 177-186
133. Loichot C., Grima M., DeJong W., Hewig J.J., Imbs J.L., and Barthelmebs M. Oxytocin-induced renin secretion by denervated kidney in anaesthetized rat. Eur. J. Pharmacol. 454 (2002) 241-247
134. 2 receptor and possible link to nephrogenic diabetes insipidus. Nature 357 (1992) 336-339
135. 7]oxytocin), and [7-Glycine]oxytocin, peptides with high oxytocic-antidiuretic selectivity. J. Med. Chem. 20 (1977) 120-123
136. Lutz W.H., Londowski J.M., and Kumar R. The synthesis and biological activity of four novel fluorescent vasopressin analogs. J. Biol. Chem. 265 (1990) 4657-4663
137. Ma S., Shipston M.J., Morilak D., and Russell J.A. Reduced hypothalamic vasopressin secretion underlies attenuated adrenocorticotropin stress responses in pregnant rats. Endocrinology 146 (2005) 1626-1637
138. Makaryus A.N., and McFarlane S.I. Diabetes insipidus: diagnosis and treatment of a complex disease. Cleve. Clin. J. Med. 73 (2006) 65-71
139. Malik D.K., Baboota S., Ahuja A., Hasan S., and Ali J. Recent advances in protein and peptide drug delivery systems. Curr. Drug Deliv. 4 (2007) 141-151
140. Manning M. Impact of the Merrifield solid phase method on the design and synthesis of selective agonists and antagonists of oxytocin and vasopressin: a historical perspective. Biopolymers (Peptide Science) 90 3 (2008) 203-212
141. Manning M., Balaspiri L., Acosta M., and Sawyer W.H. Solid phase synthesis of [1-deamino-4-valine]-8-d-arginine vasopressin (DVDAVP). A highly potent and specific antidiuretic agent possessing protracted effects. J. Med. Chem. 16 (1973) 975-978
142. Manning M., Balaspiri L., Moehring J., Haldar J., and Sawyer W.H. Synthesis and some pharmacological properties of deamino(4-threonine,8-d-arginine)vasopressin and deamino(8-d-arginine)vasopressin, highly potent and specific antidiuretic peptides, and (8-d-arginine)vasopressin and deamino-arginine-vasopressin. J. Med. Chem. 19 (1976) 842-845
143. 1a receptor antagonists of vasopressin. Int. J. Pept. Protein Res. 40 (1992) 261-267
144. Manning M., Bankowski K., and Sawyer W.H. Selective agonists and antagonists of vasopressin. In: Gash D.M., and Boer G.J. (Eds). Vasopressin (1987), Plenum Press, New York, NY 335-368
145. Manning M., Cheng L.L., Stoev S., Klis W., Nawrocka E., Olma A., Sawyer W.H., Wo N.C., and Chan W.Y. Position three in vasopressin antagonist tolerates conformationally restricted and aromatic amino acid substitutions: a striking contrast with vasopressin agonists. J. Pept. Sci. 3 (1997) 31-46
146. Manning M., Cheng L.L., Stoev S., Sawyer W.H., Tribollet E., Barberis C., Wo N.C., and Chan W.Y. Novel potent and selective antagonists and radioiodinated ligands for oxytocin and vasopressin resceptors. Recent progress of vasopressin and oxytocin research. In: Saito T., Kurokawa K., and Yoshida S. (Eds). Neurohypophysis (1995), Elsevier Science, Amsterdam 21-38
147. Manning M., Cheng L.L., Stoev S., Wo N.C., Chan W.Y., Szeto H.H., Durroux T., Mouillac B., and Barberis C. Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban. J. Pept. Sci. 11 (2005) 593-608
148. Manning M., Grzonka Z., and Sawyer W.H. Synthesis of posterior pituitary hormones and hormone analogues. In: Beardwell C., and Robertson G. (Eds). The Pituitary (1981), Butterworth, Kent, England 265-296
149. 1) responses of vasopressin. Int. J. Pept. Protein Res. 32 (1988) 455-467
150. 2 agonists: potential radioiodinated ligands for vasopressin receptors. In: Giralt E., and Andreu D. (Eds). Peptides (1990) (1991), ESCOM Science Publishers, Leiden 665-667
151. Manning M., Kruszynski M., Bankowski K., Olma A., Lammek B., Cheng L.L., Klis W.A., Seto J., Haldar J., and Sawyer W.H. Solid phase synthesis of 16 potent (selective and nonselective) in vivo antagonists of oxytocin. J. Med. Chem. 32 (1989) 382-391
152. Manning M., Miteva K., Pancheva S., Stoev S., Wo N.C., and Chan W.Y. Design and synthesis of highly selective in vitro and in vivo uterine receptor antagonists of oxytocin: comparisons with atosiban. Int. J. Peptide Protein Res. 46 (1995) 244-252
153. Manning M., Olma A., Klis W., Kolodziejczyk A., Nawrocka E., Misicka A., Seto J., and Sawyer W.H. Carboxy terminus of vasopressin required for activity but not binding. Nature 308 (1984) 652-653
154. Manning M., Olma A., Klis W.A., Kolodziejczyk A.M., Seto J., and Sawyer W.H. Design of more potent antagonists of the antidiuretic responses to arginine-vasopressin. J. Med. Chem. 25 (1982) 45-50
155. Manning M., and Sawyer W.H. Discovery, development, and some uses of vasopressin and oxytocin antagonists. J. Lab. Clin. Med. 114 (1989) 617-632 [Published erratum appears in J. Lab. Clin. Med., 115, 530, 1990.]
156. Manning M., and Sawyer W.H. Design, synthesis and some uses of receptor-specific agonists and antagonists of vasopressin and oxytocin. J. Recept. Res. 13 (1993) 195-214 Review
157. 1-receptor) response to arginine-vasopressin. J. Med. Chem. 35 (1992) 382-388
158. Manning M., Stoev S., Cheng L.L., Wo N.C., and Chan W.Y. Synthesis and structure-activity investigation of novel vasopressin hypotensive peptide agonists. J. Pept. Sci. 5 (1999) 472-490
159. Manning M., Stoev S., Cheng L.L., Wo N.C., and Chan W.Y. Design of oxytocin antagonists, which are more selective than atosiban. J. Pept. Sci. 7 (2001) 449-465
160. Manning M., Stoev S., Cheng L.L., Wo N.C., and Szeto H.H. The role of the Merrifield solid phase method in the discovery and exploration of a new class of selective vasopressin hypotensive agonists. Int. J. Pept. Res. Ther. 13 (2007) 7-17
161. 1-receptor) responses to vasopressin. J. Med. Chem. 33 (1990) 3079-3086
162. Mannucci P.M., and Levi M. Prevention and treatment of major blood loss. N. Engl. J. Med. 356 (2007) 2301-2311
163. 2-receptors in rat kidney. Endocrinology 122 (1988) 1328-1336
164. Mastrandrea L.D., and Quattrin T. Clinical evaluation of inhaled insulin. Adv. Drug. Deliv. Rev. 58 (2006) 1061-1075
165. McCafferty G.P., Pullen M.A., Wu C., Edwards R.M., Allen M.J., Woollard P.M., Borthwick A.D., Liddle J., Hickey D.M., Brooks D.P., and Westfall T.D. Use of a novel and highly selective oxytocin receptor antagonist to characterize uterine contractions in the rat. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293 (2007) R299-R305
166. McKee D.T., Poletini M.O., Bertram R., and Freeman M.E. Oxytocin action at the lactotroph is required for prolactin surges in cervically stimulated ovariectomized rats. Endocrinology 148 (2007) 4649-4657
167. Mehta N.M. Oral delivery and recombinant production of peptide hormones. Part 1: making oral delivery possible. Biopharm Int. 1-6 (2004)
168. Meinlschmidt G., and Heim C. Sensitivity to intranasal oxytocin in adult men with early parental separation. Biol. Psychiatry 61 (2007) 1109-1111
169. Melin P., Trojnar J., Johansson B., Vilhardt H., and Akerlund M. Synthetic antagonists of the myometrial response to oxytocin and vasopressin. J. Endocrinol. 111 (1986) 125-131
170. Merrifield R.B. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J. Am. Chem. Soc. 85 (1963) 2149-2154
171. Miller M.E., Davidge S.T., and Mitchell B.F. Oxytocin does not directly affect vascular tone in vessels from nonpregnant and pregnant rats. Am. J. Physiol. Heart Circ. Physiol. 282 (2002) H1223-H1228
172. Miranda-Cardenas Y., Rojas-Piloni G., Martinez-Lorenzana G., Rodriguez-Jimenez J., Lopez-Hidalgo M., Freund-Mercier M.J., and Condes-Lara M. Oxytocin and electrical stimulation of the paraventricular hypothalamic nucleus produce antinociceptive effects that are reversed by an oxytocin antagonist. Pain 122 (2006) 182-189
173. 1a vasopressin receptor. Nature 356 (1992) 523-526
174. 2 vasopressin receptor induces a constitutive activity which permits discrimination between antagonists with partial agonist and inverse agonist activities. FEBS Lett. 441 (1998) 470-475
175. Munger M.A. New agents for managing hyponatremia in hospitalized patients. Am. J. Health Syst. Pharm. 64 (2007) 253-265 Review
176. Munsick R.A. Effect of magnesium ion on the response of the rat uterus to neurohypophysial hormones and analogues. Endocrinology 66 (1960) 451-457
177. Nakamura S., Hirano T., Tsujimae K., Aoyama M., Kondo K., Yamamura Y., Mori T., and Tominaga M. Antidiuretic effects of a nonpeptide vasopressin V(2)-receptor agonist, OPC-51803, administered orally to rats. J. Pharmacol. Exp. Ther. 295 (2000) 1005-1011
178. Neumann I.D., Bosch O.J., Toschi N., Torner L., and Douglas A.J. No stress response of the hypothalamo-pituitary-adrenal axis in parturient rats: lack of involvement of brain oxytocin. Endocrinology 144 (2003) 2473-2479
179. Neumann I.D., Torner L., Toschi N., and Veenema A.H. Oxytocin actions within the supraoptic and paraventricular nuclei: differential effects on peripheral and intranuclear vasopressin release. Am. J. Physiol. Regul. Integr. Comp. Physiol. 291 (2006) R29-R36
180. Nilsson L., Reinheimer T., Steinwall M., and Akerlund M. FE 200 440: a selective oxytocin antagonist on the term-pregnant human uterus. BJOG 110 (2003) 1025-1028
181. 1 receptor and [Ca] dependent. Am. J. Physiol. Cell Physiol. 289 (2005) C283-C292
182. Ogier R., Tribollet E., Suarez P., and Raggenbass M. Identified motoneurons involved in sexual and eliminative functions in the rat are powerfully excited by vasopressin and tachykinins. J. Neurosci. 26 (2006) 10717-10726
183. Orlandi C., Zimmer C.A., and Gheorghiade M. Role of vasopressin antagonists in the management of acute decompensated heart failure. Curr. Heart Fail. Rep. 2 (2005) 131-139
184. 1b receptors: a combined pharmacological/knockout approach. Mol. Pharmacol. 65 (2004) 623-629
185. Ozkan C., Kirkpantur A., and Arici M. Tolvaptan for hyponatremia. N. Engl. J. Med. 356 (2007) 962
186. Palm C., Pistrosch F., Herbrig K., and Gross P. Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia. Am. J. Med. 119 7 (Suppl. 1) (2006) S87-S92 Review
187. Parashar A., Martinucci P., and Panesar M. Vasopressin receptor antagonists. Dial. Transplant. 36 (2007) 266-274
188. Parker K.J., Buckmaster C.L., Schatzberg A.F., and Lyons D.M. Intranasal oxytocin administration attenuates the ACTH stress response in monkeys. Psychoneuroendocrinology 30 (2005) 924-929
189. Pedersen C.A., and Boccia M.L. Oxytocin maintains as well as initiates female sexual behavior: effects of a highly selective oxytocin antagonist. Horm. Behav. 41 (2002) 170-177
190. 1b selective agonist for rat vasopressin/oxytocin receptors. Endocrinology 148 (2007) 4136-4146
191. Pena A., Murat B., Trueba M., Ventura M.A., Wo N.C., Szeto H.H., Cheng L.L., Stoev S., Guillon G., and Manning M. Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8. J. Med. Chem. 50 (2007) 835-847
192. Peng X., and Neumeyer J.L. Kappa receptor bivalent ligands. Curr. Top. Med. Chem. 7 (2007) 363-373
193. Pettibone D.J., Clineschmidt B.V., Guidotti M.T., Lis E.V., Reiss D.R., Totaro J.A., Woyden C.J., Bock M.G., Freidinger R.M., Hobbs D.W., Veber D.F., Williams P.D., Chiu S.-H.L., Thompson K.L., Schorn T.W., Siegl P.K.S., Kaufman M.J., Cukierski M.A., Haluska G.J., Cook M.J., and Novy M.J. L368,899, a potent orally active oxytocin antagonist for potential use in preterm labor. Drug Dev. Res. 30 (1993) 129-142
194. 1 receptor of rat, rhesus and human tissues. Life Sci. 50 (1992) 1953-1958
195. Pitt G.R., Batt A.R., Haigh R.M., Penson A.M., Robson P.A., Rooker D.P., Tartar A.L., Trim J.E., Yea C.M., and Roe M.B. Non-peptide oxytocin agonists. Bioorg. Med. Chem. Lett. 14 (2004) 4585-4589
196. Poulain, D., Oliet, S. and Theodosis, D. (Eds.) (2002) Vasopressin and oxytocin: from genes to clinical application. Prog. Brain Res. 139: 392.
197. Prochazka Z., and Slaninova J. The 1- and 2-naphtylalanine analogs of oxytocin and vasopressin. Collect. Czech. Chem. Commun. 60 (1995) 2170-2177
198. Purcell A.W., McCluskey J., and Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat. Rev. Drug. Discov. 6 (2007) 404-414 Review.
199. Quattropani A., Dorbais J., Covini D., Pittet P.A., Colovray V., Thomas R.J., Coxhead R., Halazy S., Scheer A., Missotten M., Ayala G., Bradshaw C., De Raemy-Schenk A.M., Nichols A., Cirillo R., Tos E.G., Giachetti C., Golzio L., Marinelli P., Church D.J., Barberis C., Chollet A., and Schwarz M.K. Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonists. J. Med. Chem. 48 (2005) 7882-7905
200. Rahman, Z., Resnick, L., Rosenzweig-Lipton, S.J. and Ring R.H. (2007) Methods of treatment using oxytocin receptor agonists. US Patent 20070117794, Kind Code: A1, Publication date 10/24/2007.
201. Reinheimer T.M. Barusiban suppresses oxytocin-induced preterm labour in non-human primates. Pregnancy Childbirth 7 Suppl. 1 (2007) S15
202. Reinheimer T.M., Bee W.H., Resendez J.C., Meyer J.K., Haluska G.J., and Chellman G.J. Barusiban, a new highly potent and long-acting oxytocin antagonist: pharmacokinetic and pharmacodynamic comparison with atosiban in a cynomolgus monkey model of preterm labor. J. Clin. Endocrinol. Metab. 90 (2005) 2275-2281
203. Reversi A., Rimoldi V., Marrocco T., Cassoni P., Bussolati G., Parenti M., and Chini B. The oxytocin receptor antagonist atosiban inhibits cell growth via a "biased agonist" mechanism. J. Biol. Chem. 280 (2005) 16311-16318
204. Reymond-Marron I., Raggenbass M., and Zaninetti M. Vasopressin facilitates glycinergic and GABAergic synaptic transmission in developing hypoglossal motoneurons. Eur. J. Neurosci. 21 (2005) 1601-1609
205. 1b receptors, and is independent of intracellular calcium signalling. Eur. J. Neurosci. 24 (2006) 1565-1574
206. Ring R.H. The central vasopressinergic system: examining the opportunities for psychiatric drug development. Curr. Pharm. Des. 11 (2005) 205-225
207. Ring, R.H. (2007) Behavioral profile of a non-peptide oxytocin receptor agonist: therapeutic implications. Oral presentation at 2007 World Congress of Neurohypophysial Hormones, Regensburg, Germany, Abstract S11-1, p. 62.
208. Ring R.H., Malberg J.E., Potestio L., Ping J., Boikess S., Luo B., Schechter L.E., Rizzo S., Rahman Z., and Rosenzweig-Lipson S. Anxiolytic-like activity of oxytocin in male mice: behavioral and autonomic evidence, therapeutic implications. Psychopharmacology 185 (2006) 218-225
209. 2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus. Am. J. Physiol. Renal Physiol. 292 (2007) F253-F260
210. 3 receptor by a pharmacological chaperone. J. Biol. Chem. 280 (2005) 42198-42206
211. 1b vasopressin receptors. Mol. Endocrinol. 21 (2007) 512-523
212. Rojas-Piloni G., Lopez-Hidalgo M., Martinez-Lorenzana G., Rodriguez-Jimenez J., and Condes-Lara M. GABA-mediated oxytocinergic inhibition in dorsal horn neurons by hypothalamic paraventricular nucleus stimulation. Brain Res. 1137 (2007) 69-77
213. Romero R., Sibai B.M., Sanchez-Ramos L., Valenzuela G.J., Veille J.C., Tabor B., Perry K.G., Varner M., Goodwin T.M., Lane R., Smith J., Shangold G., and Creasy G.W. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double-blind, placebo-controlled trial with tocolytic rescue. Am. J. Obstet. Gynecol. 182 (2000) 1173-1183
214. Ruffolo Jr. R.R., Brooks D.P., Huffman W.F., and Poste G. From vasopressin antagonist to agonist: a saga of surprise!. Drug News Perspect. 4 (1991) 217-222
215. 1b receptor: evidence for its expression in extra-pituitary tissues. Biochem. Biophys. Res. Commun. 212 (1995) 751-757
216. 1b vasopressin receptor. Biochem. Pharmacol. 53 (1997) 1711-1717
217. In: Saito T., Kurokawa K., and Yoshida S. (Eds). Neurohypophysis: Recent Progress of Vasopressin and Oxytocin Research (1995), Elsevier Science B.V., Amsterdam 1-689
218. Salomon Y., Londos C., and Rodbell M. A highly sensitive adenylate cyclase assay. Anal. Biochem. 58 (1974) 541-548
219. Sawyer W.H. Biologic assays for oxytocin and vasopressin. Methods Med. Res. 9 (1961) 210-219
220. Sawyer W.H., Acosta M., Balaspiri L., Judd J., and Manning M. Structural changes in the arginine vasopressin molecule that enhance antidiuretic activity and specificity. Endocrinology 94 (1974) 1106-1115
221. 2 vasopressin antagonists with structural changes at their C-terminals. Peptides 9 (1988) 157-163
222. Sawyer W.H., and Manning M. Experimental uses of neurohypophysial hormone analogs. Trends Endocrinol. Metab. 1 (1988) 48-50
223. Sawyer W.H., Pang P.K.T., Seto J., McEnroe M., Lammek B., and Manning M. Vasopressin analogs that antagonize antidiuretic responses by rats to the antidiuretic hormone. Science 212 (1981) 49-51
224. Schild H.O. pA, a new scale of the measurement of drug antagonism. Br. J. Pharmacol. Chemother. 2 (1947) 189-206
225. 1a receptors. FEBS Lett. 282 (1991) 77-81
226. 2-receptor antagonist, for hyponatremia. N. Engl. J. Med. 355 (2006) 2099-2112
227. Schwartz J., Derdowska I., Sobocinska M., and Kupryszewski G. A potent new synthetic analog of vasopressin with relative agonist specificity for the pituitary. Endocrinology 129 (1991) 1107-1109
228. Schwarz E.R., and Sanghi P. Conivaptan: a selective vasopressin antagonist for the treatment of heart failure. Expert Rev. Cardiovasc. Ther. 4 (2006) 17-23
229. 2 receptor antagonist. J. Clin. Invest. 98 (1996) 2729-2738
230. 1b receptor ligand. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293 (2007) R938-R949
231. 2 receptor antagonist, [H]-SR 121463. Kidney Int. 58 (2000) 1613-1622
232. Serradeil-Le Gal C., Valette G., Foulon L., Germain G., Advenier C., Naline E., Bardou M., Martinolle J.P., Pouzet B., Raufaste D., Garcia C., Double-Cazanave E., Pauly M., Pascal M., Barbier A., Scatton B., Maffrand J.P., and Le Fur G. SSR126768A (4-chloro-3-[3R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2-oxo-2,3 -dihydro-1H-indol-3-yl]-N-(3-pyridylmethyl)-benzamide, hydrochloride): a new selective and orally active oxytocin receptor antagonist for the prevention of preterm labor. J. Pharmacol. Exp. Ther. 309 (2004) 414-424
233. 1a receptors. J. Clin. Invest. 92 (1993) 224-231
234. 1b receptor antagonist. J. Pharmacol. Exp. Ther. 300 (2002) 1122-1130
235. 1b) receptor antagonist for the treatment of stress-related disorders. CNR Drug Rev. 11 (2005) 53-68 Review
236. 1b receptor ligands. Prog. Brain Res. 139 (2002) 197-210 Review
237. Shackel N., and McCaughan G. Treatment for cirrhosis-associated hyponatremia? Vaptans and aquaresis. Hepatology 45 (2007) 1080-1081
238. Smith M.P., Ayad V.J., Mundell S.J., McArdle C.A., Kelly E., and López Bernal A. Internalization and desensitization of the oxytocin receptor is inhibited by dynamin and clathrin mutants in human embryonic kidney 293 cells. Mol. Endocrinol. 20 (2006) 379-388
239. 2-receptor antagonist. Clin. J. Am. Soc. Nephrol. 1 (2006) 1154-1160
240. Stewart J.M., and Young J.D. Solid Phase Synthesis (1984), Pierce Chemical Company, Rockford, IL
241. Stoev S., Cheng L.L., Manning M., Wo N.C., and Szeto H.H. Design and synthesis of potent, highly selective vasopressin hypotensive agonists. J. Pept. Sci. 12 (2006) 592-604
242. Stoev S., Cheng L.L., Olma A., Klis W.A., Manning M., Sawyer W.H., Wo N.C., and Chan W.Y. An investigation of position 3 in arginine vasopressin with aliphatic, aromatic, conformationally-restricted, polar and charged amino acids. J. Pept. Sci. 5 (1999) 141-153
243. 1a vasopressin antagonist and its use in characterizing receptor/G protein interactions. Mol. Pharmacol. 51 (1997) 217-224
244. Streefkerk J.O., and van Zwieten P.A. Vasopressin receptor antagonists: pharmacological tools and potential therapeutic agents. Auton. Autacoid Pharmacol. 26 (2006) 141-148
245. Stymiest J.L., Mitchell B.F., Wong S., and Vederas J.C. Synthesis of oxytocin analogues with replacement of sulfur by carbon gives potent antagonists with increased stability. J. Org. Chem. 70 (2005) 7799-7809
246. Su L., Chong Y., and Samuel M. Oxytocin agonists for preventing postpartum haemorrhage. Cochrane Database Syst. Rev. 18 (2007) CD005457
247. Subburaju S., and Aguilera G. Vasopressin mediates mitogenic responses to adrenalectomy in the rat anterior pituitary. Endocrinology 148 (2007) 3102-3110
248. 1b vasopressin receptor. J. Biol. Chem. 269 (1994) 27088-27092
249. Tabrizchi R., and Ford C.A. A comparison between haemodynamic effects of vasopressin analogues. Naunyn Schmiedebergs Arch. Pharmacol. 370 (2004) 340-346
250. 2 receptor-mediated vasodilation in healthy humans. J. Cardiovasc. Pharmacol. 25 (1995) 387-392
251. 2 receptor antagonist. Naunyn Schmiedebergs Arch. Pharmacol. 357 (1998) 63-69
252. 2 receptor antagonist, in vitro and in vivo. J. Pharmacol. Exp. Ther. 282 (1997) 301-308
253. Tahara A., Tsukada J., Ishii N., Tomura Y., Wada K., Kusayama T., Yatsu T., Uchida W., and Tanaka A. Characterization of rodent liver and kidney AVP receptors: pharmacologic evidence for species differences. Regul. Pept. 84 (1999) 13-19
254. 1a receptor-selective antagonist, on human vasopressin and oxytocin receptors. Pharmacol. Res. 51 (2005) 275-281
255. Tan T.C., Devendra K., Tan L.K., and Tan H.K. Tocolytic treatment for the management of preterm labour: a systematic review. Singapore Med. J. 47 (2006) 361-366
256. Terrillon S., Cheng L.L., Stoev S., Mouillac B., Barberis C., Manning M., and Durroux T. Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J. Med. Chem. 45 (2002) 2579-2588
257. 2 receptors form constitutive homo- and heterodimers during biosynthesis. Mol. Endocrinol. 17 (2003) 677-691
258. 1a vasopressin receptor. J. Biol. Chem. 269 (1994) 3304-3310
259. 1-vascular vasopressin antagonists suitable for radioiodination, biotinylation, and fluorescent labeling. Am. J. Physiol. 265 (1993) E906-E913
260. Thibonnier M., Coles P., Thibonnier A., and Shoham M. The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists. Ann. Rev. Pharmacol. Toxicol. 41 (2001) 175-202
261. 3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways. Endocrinology 138 (1997) 4109-4122
262. 2 receptor binding is down-regulated during renal escape from vasopressin-induced antidiuresis. Endocrinology 141 (2000) 307-314
263. 1a receptors in rat hepatocytes with a fluorescent linear antagonist. J. Histochem. Cytochem. 47 (1999) 401-410
264. Treschan T.A., and Peters J. The vasopressin system: physiology and clinical strategies. Anesthesiology 105 (2006) 599-612
265. 5[d- Ileu2,Ileu4]AVP: an AVP V2 receptor antagonist radioligand. Peptides 12 (1991) 1195-1200
266. Tsatsaris V., Cabrol D., and Carbonne B. Pharmacokinetics of tocolytic agents. Clin. Pharmacokinet. 43 (2004) 833-844
267. Tsukada J., Tahara A., Tomura Y., Wada K., Kusayama T., Ishii N., Aoki M., Yatsu T., Uchida W., Taniguchi N., and Tanaka A. Pharmacological characterization of YM471, a novel potent vasopressin V(1A) and V(2) receptor antagonist. Eur. J. Pharmacol. 446 (2002) 129-138
268. Valenzuela G.J., Sanchez-Ramos L., Romero R., Silver H.M., Koltun W.D., Millar L., Hobbins J., Rayburn W., Shangold G., Wang J., Smith J., and Creasy G.W. Maintenance treatment of preterm labor with the oxytocin antagonist atosiban. The Atosiban PTL-098 Study Group. Am. J. Obstet. Gynecol. 182 (2000) 1184-1190
269. 2 receptor defect. J. Hypertens. 13 (1995) 1695-1700
270. Vatish M., and Thornton S. Oxytocin antagonists. Expert Opin. Ther. Pat. 12 (2002) 1403-1406
271. Verbalis J.G. AVP receptor antagonists as aquaretics: review and assessment of clinical data. Cleve. Clin. J. Med. 73 (2006) S24-S33 Review
272. Verlander M. Large scale production of peptides - the success story. In: Flegel M., Fritkin M., Gilon C., and Slaninova J. (Eds). Peptides (2004) (2005), Kenes International, Geneva 54-58
273. 1b receptor promoter through transactivation of the MAP kinase pathway. J. Mol. Endocrinol. 36 (2006) 581-590
274. Waldherr M., and Neumann I.D. Centrally released oxytocin mediates mating-induced anxiolysis in male rats. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 16681-16684
275. Walker B.R., Haynes Jr. J., Wang H.L., and Voelkel N.F. Vasopressin-induced pulmonary vasodilation in rats. Am. J. Physiol. 257 (1989) H415-H422
276. Walter K.A. Conivaptan: new treatment for hyponatremia. Am. J. Health Syst. Pharm. 64 (2007) 1385-1395
277. Weise W.J., Rimmer J.M., and Hood V.L. Tolvaptan for hyponatremia. N. Engl. J. Med. 356 (2007) 961
278. Williams P.D., Clineschmidt B.V., Erb J.M., Freidinger R.M., Guidotti M.T., Lis E.V., Pawluczyk J.M., Pettibone D.J., Reiss D.R., Veber D.F., and Woyden C.Y. 1-(1-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4-yl)-4H-3 ,1-benzoxazin-2(1H)-one (L-371-257): a new, orally bioavailable, non-peptide oxytocin antagonist. J. Med. Chem. 38 (1995) 4634-4636
279. Wilson R.J., Allen M.J., Nandi M., Giles H., and Thornton S. Spontaneous contractions of myometrium from humans, non-human primate and rodents are sensitive to selective oxytocin receptor antagonism in vitro. Br. J. Obstet. Gynaecol. 108 (2001) 960-966
280. Windle R.J., Gamble L.E., Kershaw Y.M., Wood S.A., Lightman S.L., and Ingram C.D. Gonadal steroid modulation of stress-induced hypothalamo-pituitary-adrenal activity and anxiety behavior: role of central oxytocin. Endocrinology 147 (2006) 2423-2431
281. 2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J. Pharmacol. Exp. Ther. 287 (1998) 860-867
282. 1 receptor antagonist. Science 252 (1991) 572-574
283. 2 receptor antagonist. Br. J. Pharmacol. 105 (1992) 787-791
284. 1 receptor relating to endogenous opiate peptides, arginine vasopressin in periaqueductal gray regulates antinociception in the rat. Regul. Pept. 137 (2006) 156-161
285. Yu M., Ghosh M., and McNeill J.R. A novel vasopressin peptide lowers blood pressure through decreases in cardiac output. Can. J. Physiol. Pharmacol. 81 (2003) 497-501
286. Zaoral M., Kolc J., and Sorm F. Amino acids and peptides. LXXI. Synthesis of 1-deamino-8-d-γ-aminobutyrine-vasopressin. 1-deamino-8-d-lysine-vasopressin, and 1-deamino-8-d-arginine-vasopressin. Collect. Czech. Chem. Commun. 32 (1967) 1250-1257
287. Zingg, H.H., Bourne, C.W. and Bichet, D.G. (Eds.) (1998) Vasopressin and oxytocin. Molecular, cellular and clinical advances. Adv. Exp. Med. Biol. 449: 1-483.
288. Zuberi B.F. Hemodynamic effects of terlipressin in patients with bleeding esophageal varices secondary to cirrhosis of liver. J. Coll. Physicians Surg. Pak. 17 (2007) 388-389